Overview

Title

To amend the Public Health Service Act to authorize a grant program to provide surge capacity for providers faced with increased unmet need for contraceptive care.

ELI5 AI

H.R. 9807 is like a big plan to give places like hospitals extra money to help people get the medicine they need to not have babies if they don't want to. They want to make sure everyone, especially in communities that don't have much, can get this help easily.

Summary AI

H.R. 9807 proposes an amendment to the Public Health Service Act to establish a grant program aimed at increasing the availability of contraceptive care in areas with high unmet needs. The bill highlights the importance of equitable access to contraceptive services, especially for underserved communities, and intends to provide funding of $100 million annually from 2025 to 2029. The grants would be available to various entities, such as hospitals and clinics, to enhance contraceptive care through education, supply, and counseling services. Priority will be given to areas with the highest need and those already receiving Title X funding.

Published

2024-09-25
Congress: 118
Session: 2
Chamber: HOUSE
Status: Introduced in House
Date: 2024-09-25
Package ID: BILLS-118hr9807ih

Bill Statistics

Size

Sections:
4
Words:
1,724
Pages:
9
Sentences:
35

Language

Nouns: 508
Verbs: 141
Adjectives: 113
Adverbs: 25
Numbers: 57
Entities: 86

Complexity

Average Token Length:
4.33
Average Sentence Length:
49.26
Token Entropy:
5.30
Readability (ARI):
26.85

AnalysisAI

The "Strengthening Access to Contraceptive Care Act," also known as H.R. 9807, seeks to amend the Public Health Service Act. Its primary goal is to establish a grant program designed to increase the capacity of healthcare providers to offer contraceptive care. This initiative is motivated by a recognized unmet need for contraceptive services, particularly in areas designated as "contraceptive deserts" where access to a full range of contraceptive methods is limited. The bill proposes to allocate $100 million annually from 2025 to 2029 to support this effort. Eligible recipients of the grants include hospitals, clinics, and other organizations that provide contraceptive counseling and services.

Significant Issues

One of the key issues with H.R. 9807 is the lack of specific criteria for how grant funds should be allocated. While the bill earmarks $100 million per year, it does not provide detailed plans on how these funds should be overseen or distributed effectively, raising concerns about potential inefficiencies.

The eligibility criteria for grant recipients are broad, allowing both governmental and non-governmental organizations to apply. This wide scope might lead to dilution of funds, possibly reducing the impact in areas that need it most, if not properly managed.

Another area of concern is the lack of clarity in defining an "increased unmet need for contraceptive services," leaving room for subjective interpretation. Additionally, the process for applying for these grants is vague, which could result in inconsistencies in the distribution of funds.

The bill also overlaps with existing programs under Title X of the Public Health Service Act without clearly distinguishing the differences, possibly resulting in redundant funding. Moreover, the proposal to triple the current funding level for Title X is asserted without a detailed justification.

Lastly, the bill does not address potential conscience-based objections from providers who may not support certain services, which could limit participation from diverse healthcare providers.

Impact on the Public

The intended broad impact of this bill is to improve access to contraceptive care across the United States, particularly in underserved areas. By bolstering the capacity of healthcare providers, the bill aims to offer essential services to those who currently lack them.

However, the effectiveness of this bill will largely depend on the execution of grant allocation and monitoring. Without specific guidelines and oversight, the allocated funds might not reach the areas of greatest need, limiting the intended benefit to the public.

Impact on Stakeholders

For healthcare providers, particularly those in underserved regions, this bill presents an opportunity to enhance their services with additional funding. It could enable them to expand educational outreach, improve telehealth services, and increase the availability of contraceptive supplies.

On the other hand, the wide eligibility criteria and lack of clear priorities might mean that some institutions, especially smaller or rural ones, could face challenges in competing for these grants. Furthermore, providers with moral or ethical reservations about certain contraceptive services might find themselves excluded from grant opportunities, potentially limiting the breadth of service providers involved in the program.

Individuals living in contraceptive deserts stand to gain considerably from this legislation if it is effectively implemented, but they might see little change if funds are misallocated or mismanaged due to undefined criteria and oversight issues. The bill's focus on addressing systemic barriers such as racism and discrimination is crucial, yet it lacks a detailed plan on how to directly tackle these specific disparities.

In conclusion, while the "Strengthening Access to Contraceptive Care Act" has ambitious aims to address a pressing public health issue, it requires more detailed planning and clearer guidelines to ensure that its goals are met and that stakeholders are positively impacted.

Financial Assessment

The bill, H.R. 9807, proposes a fiscal allocation related to enhancing contraceptive care across the United States, particularly targeting areas with high unmet needs. The financial component of this bill is significant, emphasizing a structured approach toward addressing contraceptive deserts and promoting equitable access to contraceptive services.

Financial Summary

H.R. 9807 authorizes an appropriation of $100 million annually from 2025 to 2029. This funding is designed to establish a grant program aimed at increasing the capacity of entities such as hospitals, clinics, and various organizations to provide comprehensive contraceptive care. This allocation underscores the bill's focus on tackling disparities in access to contraceptive services by financially supporting areas and entities with demonstrated needs.

Financial Allocation Concerns

A critical point raised pertains to the lack of detailed allocation plans accompanying the $100 million annual appropriation (Section 3, Subsection h). This absence could lead to concerns regarding oversight, effectiveness, and efficiency in the use of these funds. Without concrete strategies or oversight mechanisms, there could be potential misuse or inefficient use of the allocated monies.

Potential for Redundancy

The bill prioritizes entities already receiving Title X funding, indicating potential overlaps with existing programs (Section 3, Subsection c). This overlap raises the risk of redundant spending, where funds might be used to finance already funded actions or services, thus not expanding the reach but merely supplementing existing initiatives. It is essential to ensure that this funding complements Title X efforts rather than duplicates them.

Eligibility and Transparency

The section describing eligible entities (Section 3, Subsection 340A-1, Subsection b) is broad, allowing a wide range of potential recipients. This broad eligibility could lead to diluting the impact of funds, with resources potentially spread too thinly across many entities. The absence of specific criteria defining "increased unmet need for contraceptive services" also introduces a layer of subjectivity and potential inequity in grant distribution. Furthermore, the vague nature of the application process (Section 3, Subsection e) leaves room for ambiguity and potential favoritism, potentially affecting the fairness and transparency of fund allocation.

Issues of Fund Justification

During the findings section, the bill asserts that Title X funding levels need to be tripled to meet current demands without providing a detailed justification for this figure. This lack of explanation may lead to skepticism about whether the specified funding adequately addresses the unmet needs or if it might be overstated. Ensuring transparency in how these figures are derived would bolster trust in the financial requests made by the bill.

In conclusion, while the bill proposes significant financial investments aimed at increasing access to contraceptive services, its implementation would benefit from enhanced specificity, transparency, and accountability mechanisms to ensure these funds meet their intended goals effectively and efficiently.

Issues

  • The bill authorizes $100,000,000 annually for five years (Section 3, Subsection h) without detailed allocation plans, which could lead to concerns about oversight and ensuring funds are used effectively and efficiently.

  • The section detailing 'Grants to increase access to contraceptive care' (Section 3, Subsection 340A-1) does not specify criteria for determining 'increased unmet need for contraceptive services,' leaving room for ambiguity or favoritism in grant distribution.

  • The eligible entities section (Section 3, Subsection 340A-1, Subsection b) includes a wide range of potential recipients, which might dilute funds and lead to less impactful spending without proper prioritization or monitoring.

  • The application process (Section 3, Subsection e) is vague, stating it must be 'at such time, in such manner, and containing such information as the Secretary may require,' which could result in subjectivity or lack of transparency in application requirements.

  • The overlap of funding with existing programs such as title X of the Public Health Service Act (Section 3, Subsection c, and general discussion in findings) could lead to redundant spending.

  • The statement of the need for more than three times the current level of funding for title X (Section 2, Findings) is made without detailed justification, potentially leading to skepticism about the specified funding requirement.

  • The bill does not address 'conscience-based objections' (Section 3, Subsection 340A-1), potentially excluding some providers from accessing funds if they have objections to providing certain services, which might limit access in some areas.

  • The lack of enforcement mechanisms to ensure compliance with requirements for unbiased and medically accurate information (Section 3, Subsection 340A-1) could undermine the integrity and effectiveness of the grant program.

Sections

Sections are presented as they are annotated in the original legislative text. Any missing headers, numbers, or non-consecutive order is due to the original text.

1. Short title Read Opens in new tab

Summary AI

This section of the bill is the short title, stating that the legislation can be referred to as the “Strengthening Access to Contraceptive Care Act.”

2. Findings Read Opens in new tab

Summary AI

Congress finds that a large portion of the population lacks access to comprehensive contraceptive care, particularly among women, transgender, and nonbinary individuals in "contraceptive deserts." They highlight the impact of systemic issues like racism and underfunded family planning programs, and suggest the need for significant investments to improve access to contraception.

3. Grants to increase access to contraceptive care Read Opens in new tab

Summary AI

The bill section authorizes the Secretary of Health and Human Services to establish a grant program to help hospitals, clinics, and other organizations increase access to contraceptive care, prioritizing those in areas with higher unmet needs. The funds can be used for activities like patient education, purchasing contraceptives, providing counseling, telehealth services, and hiring staff, with an allocation of $100 million annually from 2025 to 2029.

Money References

  • Such term includes any device, medication, procedure, or behavior listed in the most recently published Birth Control Guide published by the Food and Drug Administration, including— “(A) sterilization surgery for women; “(B) implantable rods; “(C) copper intrauterine devices; “(D) intrauterine devices with progestin; “(E) injectable contraceptives; “(F) oral contraceptives (combined pill); “(G) oral contraceptives (progestin only); “(H) oral contraceptives (extended or continuous use); “(I) contraceptive patch; “(J) vaginal contraceptive rings; “(K) diaphragms; “(L) contraceptive sponges; “(M) cervical caps; “(N) condoms; “(O) spermicides; “(P) emergency contraception (levonorgestrel); “(Q) emergency contraception (ulipristal acetate); and “(R) any additional contraceptives approved, granted marketing authorization, or cleared under the Federal Food, Drug, and Cosmetic Act or licensed under section 351 of this Act. “(h) Authorization of appropriations.—To carry out this section, there is authorized to be appropriated $100,000,000 for each of fiscal years 2025 through 2029.”. ---

340A–1. Grants to increase access to contraceptive care Read Opens in new tab

Summary AI

The section outlines a grant program aimed at increasing access to contraceptive care by providing funds to eligible entities such as hospitals, clinics, and nonprofit organizations. These grants can be used to educate patients, purchase contraceptive supplies, offer counseling, and expand services like telehealth, with an emphasis on areas demonstrating increased unmet need or entities previously funded under a related federal program.

Money References

  • Such term includes any device, medication, procedure, or behavior listed in the most recently published Birth Control Guide published by the Food and Drug Administration, including— (A) sterilization surgery for women; (B) implantable rods; (C) copper intrauterine devices; (D) intrauterine devices with progestin; (E) injectable contraceptives; (F) oral contraceptives (combined pill); (G) oral contraceptives (progestin only); (H) oral contraceptives (extended or continuous use); (I) contraceptive patch; (J) vaginal contraceptive rings; (K) diaphragms; (L) contraceptive sponges; (M) cervical caps; (N) condoms; (O) spermicides; (P) emergency contraception (levonorgestrel); (Q) emergency contraception (ulipristal acetate); and (R) any additional contraceptives approved, granted marketing authorization, or cleared under the Federal Food, Drug, and Cosmetic Act or licensed under section 351 of this Act. (h) Authorization of appropriations.—To carry out this section, there is authorized to be appropriated $100,000,000 for each of fiscal years 2025 through 2029. ---